2020.07.09 02:20
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18193 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32343 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5920 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43838 |
8842 | 영화 Out of Africa...Stay with me till the morning/Dana Winner | 2005.03.13 | jinsoo | 2005.03.13 | 13237 |
8841 | [re] A Memory of Africa with a song | 2005.03.14 | Steven Kim | 2005.03.14 | 7622 |
8840 | 봄이 오면 | 2005.03.24 | 이한중 | 2005.03.24 | 7757 |
8839 | 코리아 여! [8] | 2005.03.25 | 이 한 중 | 2016.06.16 | 7622 |
8838 | Rumination over pictures of old faces from Orlando [2] | 2005.03.27 | Oun Kwon 권 오 언 | 2016.06.15 | 7795 |
8837 | 제비 - La Golondrina (노래감상) [1] | 2005.03.29 | Steven Kim | 2005.03.29 | 9302 |
8836 | 복 수 초 [7] | 2005.03.29 | 오세윤 | 2005.03.29 | 7346 |
8835 | 진달래 꽃 (素月의 詩와 인생) [3] | 2005.04.02 | Steven Kim | 2005.04.02 | 7597 |
8834 | [시해설] 김소월 : 진달래꽃 [4] | 2005.04.03 | 김 원호 | 2005.04.03 | 9198 |
8833 | Golfing with Friends [9] | 2005.04.03 | 이 한 중 | 2005.04.03 | 7289 |
8832 | [re] Golfing with Friends [4] | 2005.04.04 | jinsoo | 2005.04.04 | 6911 |
8831 | 조금씩 아름다워 지는 사람(퍼옴) [1] | 2005.04.05 | 석주 | 2005.04.05 | 7892 |
8830 | [re] 조금씩 아름다워 지는 사람 [5] | 2005.04.05 | jinsoo | 2005.04.05 | 7059 |
8829 | L'amour, c'est pour rien! [5] | 2005.04.05 | 通信兵 | 2005.04.05 | 7659 |
8828 | 징 검 다리 - 오세윤 [3] | 2005.04.10 | 오세윤 | 2016.06.17 | 7339 |
8827 | [시 감상] 행복 - 유치환 [5] | 2005.04.13 | kyu hwang | 2005.04.13 | 8144 |
8826 | 좋은 친구는 인생에서 가장 큰 보배 [5] | 2005.04.16 | 물안개 | 2005.04.16 | 6378 |
8825 | 어머니 (법정스님의 글) [2] | 2005.04.16 | 一水去士 | 2016.06.17 | 7007 |
8824 | [re] 어머니 만나고 온 날 [3] | 2005.04.16 | 물안개 | 2005.04.16 | 7003 |
8823 | 그립다 말을 할까 [6] | 2005.04.17 | 오세윤 | 2005.04.17 | 6969 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)